Jeenduang Nutjaree, Horpet Dararat, Plyduang Thunyaluk, Nuinoon Manit
School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand.
Food Technology and Innovation Research Center of Excellence, Walailak University, Nakhon Si Thammarat, Thailand.
Heliyon. 2024 May 16;10(10):e31374. doi: 10.1016/j.heliyon.2024.e31374. eCollection 2024 May 30.
This study explored the frequency of lipid-lowering drug use in the thalassemia population and investigated the association of thalassemia, hemoglobinopathies, and serum 25(OH)D levels with lipid profile and red blood cell parameters. A combination of cross-sectional and community-based studies was conducted with 615 participants from the southern Thai population. Thalassemia and hemoglobinopathies were diagnosed using hemoglobin analysis and polymerase chain reaction-based methods to genotype globin genes. Biochemical parameters such as lipid profile, fasting blood sugar (FBS), and serum 25(OH)D levels were assessed using standard enzymatic methods and electrochemiluminescence immunoassays. Differences in the means of hematological and biochemical parameters between the thalassemia and non-thalassemia groups were compared and analyzed. A significantly lower frequency of lipid-lowering drug use was observed in the thalassemia group. Thalassemia, with clearly defined abnormalities in red blood cells, is associated with a 4.72-fold decreased risk of taking lipid-lowering drugs. Among thalassemia participants, the total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were significantly lower than those in non-thalassemia participants. The prevalence of hypovitaminosis D in carriers of thalassemia and/or hemoglobinopathies in the southern Thai population was 53 % in females and 21 % in males. The highest lipid profile was observed in samples without thalassemia and hypovitaminosis D. The genetics of thalassemia and hemoglobinopathies with obviously abnormal red blood cells could explain the variable lipid levels, in addition to lipid metabolism-related genes and environmental factors. However, the effect of thalassemia on lipid levels in each population may differ according to its prevalence. A larger sample size is required to confirm this association, especially in countries with a high prevalence of thalassemia.
本研究探讨了地中海贫血人群中降脂药物的使用频率,并调查了地中海贫血、血红蛋白病和血清25(OH)D水平与血脂谱及红细胞参数之间的关联。对来自泰国南部人群的615名参与者进行了横断面研究和社区研究相结合的调查。采用血红蛋白分析和基于聚合酶链反应的方法对球蛋白基因进行基因分型,以诊断地中海贫血和血红蛋白病。使用标准酶法和电化学发光免疫分析法评估血脂谱、空腹血糖(FBS)和血清25(OH)D水平等生化参数。比较并分析了地中海贫血组和非地中海贫血组血液学和生化参数均值的差异。在地中海贫血组中观察到降脂药物的使用频率显著较低。地中海贫血患者红细胞存在明确异常,其服用降脂药物的风险降低了4.72倍。在地中海贫血参与者中,总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)水平显著低于非地中海贫血参与者。泰国南部人群中,地中海贫血和/或血红蛋白病携带者维生素D缺乏症的患病率女性为53%,男性为21%。在无地中海贫血和维生素D缺乏症的样本中观察到最高的血脂谱。除了脂质代谢相关基因和环境因素外,红细胞明显异常的地中海贫血和血红蛋白病的遗传学特征可以解释血脂水平的差异。然而,地中海贫血对各人群血脂水平的影响可能因其患病率而异。需要更大的样本量来证实这种关联,尤其是在地中海贫血患病率较高的国家。